Turning Point Therapeutics (NASDAQ:TPTX) insider Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $52.94, for a total value of $608,810.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Jingrong Jean Cui also recently made the following trade(s):
- On Monday, December 9th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $55.32, for a total transaction of $636,180.00.
- On Thursday, December 5th, Jingrong Jean Cui sold 56,110 shares of Turning Point Therapeutics stock. The shares were sold at an average price of $51.95, for a total transaction of $2,914,914.50.
TPTX stock opened at $55.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 36.64 and a current ratio of 36.64. The company’s 50 day moving average is $48.31 and its 200 day moving average is $43.08. Turning Point Therapeutics has a 1-year low of $24.21 and a 1-year high of $58.56.
Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $25,000. Rhumbline Advisers grew its position in Turning Point Therapeutics by 15.7% in the third quarter. Rhumbline Advisers now owns 6,729 shares of the company’s stock worth $253,000 after acquiring an additional 911 shares in the last quarter. Wells Fargo & Company MN purchased a new position in Turning Point Therapeutics in the second quarter worth $72,000. JPMorgan Chase & Co. bought a new position in Turning Point Therapeutics in the second quarter valued at $71,000. Finally, Cubist Systematic Strategies LLC bought a new position in Turning Point Therapeutics in the second quarter valued at $90,000. 66.79% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Turning Point Therapeutics in a research note on Tuesday. Wedbush started coverage on shares of Turning Point Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $63.00 target price on the stock. Roth Capital began coverage on shares of Turning Point Therapeutics in a report on Thursday, November 14th. They issued a “buy” rating and a $65.00 price target for the company. Zacks Investment Research upgraded shares of Turning Point Therapeutics from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Friday, November 8th. Finally, Wells Fargo & Co upped their price target on shares of Turning Point Therapeutics from $53.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Eleven equities research analysts have rated the stock with a buy rating, Turning Point Therapeutics currently has an average rating of “Buy” and an average target price of $55.00.
About Turning Point Therapeutics
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Recommended Story: What is a price target?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.